Company Profile
Updated: 11-NOV-09Novartis International AG
International public company
St. Johann, Basel, CH-4002, Switzerland
()41 061 324 84 33, 41 061 324 80 01 fax, http://www.novartis.com
Primary SIC: Industrial Inorganic Chemicals, Not Elsewhere Classified, Primary NAICS: Inorganic Dye and Pigment Manufacturing
Description: Manufacturing: Development, manufacture and marketing of a wide range of chemical products for healthcare (pharmaceuticals, generic drugs, lens care); consumer health (OTC, health and functional and medical nutrition) and animal health. The company is organised into the following units: Pharmaceuticals; Generics; Consumer Health; Ciba Vision; Animal Health
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Research on hematopoietic reported by M. Xaymardan et al.(Report)
Blood Weekly; 11/19/2009; 882 words; ...inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, http://www.novartis.com), to the culture. Cluster formation...Imatinib, Imatinib Mesylate, Kinase, Novartis AG, Pharmaceutical Business, Pharmaceutical...
Researchers from Novartis describe findings in pharmacokinetics.(Clinical report)
Biotech Week; 11/18/2009; 902 words; ...avosentan in man. International Journal of Clinical...contact T. Hengelage, Novartis Pharma AG, Clinic Development...information for the International Journal of Clinical...Pharmacology, Drugs, Novartis AG, Pharmaceutical Business...
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial.
PR Newswire; 11/16/2009; 1226 words; ...inhibits tissue proliferation. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has...
USPTO Issues Trademark YNOVAD to Novartis for Pharmaceutical Preparations
US Fed News Service, Including US State News; 11/13/2009; 411 words; ALEXANDRIA, Va., Nov. 13 -- Novartis AG Societe anonyme SWITZERLAND, Basel, Switzerland, has been issued the trademark YNOVAD (Reg. No. 3708962; International Reg. No. 0996820) by the USPTO. The trademark application...
Publication No. WO/2009/135526 Published on Nov. 12, Assigned to Novartis for Alpha-Mercapto-amides (Swiss, Italian, German Inventors)
US Fed News Service, Including US State News; 11/13/2009; 368 words; ...mercapto-amides. The patent has been assigned to Novartis AG, Basel, Switzerland. According to an abstract posted...inhibitors and are highly potent." The invention carries International Patent Publication No. WO/2009/135526 on Nov...
Recent News Articles
- Intellikine raises $51m in quest for cancer drug.(Novartis International AG. Novartis BioVenture Fund)(Brief article)
San Diego Business Journal - July 13, 2009 - Novartis increases compound artemether output.(Novartis International AG)(Brief article)
China Chemical Reporter - March 16, 2006 - Webcast Alert: Novartis AG Presentation at Informed Investors International Pharmaceuticals Virtual Forum to be Webcast on Tuesday, November 9, 2004, 3:00 pm ET.
Business Wire - November 09, 2004 - SEBIO Investor Forum Announces Speakers for Sixth Annual Conference; Speakers from Novartis International AG and Perseus-Soros Biopharmaceuticals Fund.
Business Wire - October 20, 2004
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
Related Company Profiles
- Vinilos Y Mangueras S.A. de C.V.
- Visaplast S.A. de C.V.
- Industrial Development Corporation of Zimbabwe Ltd.